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Diagnostic ultrasound (DUS) pressures have the ability to induce inertial cavitation (IC) of systemically administered
microbubbles; this bioeffect has many diagnostic and therapeutic implications in cardiovascular care. Diagnostically,
commercially available lipid-encapsulated perfluorocarbons (LEP) can be utilized to improve endocardial and
vascular border delineation as well as assess myocardial perfusion. Therapeutically, the liquid jets induced by IC can
alter endothelial function and dissolve thrombi within the immediate vicinity of the cavitating microbubbles. The
cavitating LEP can also result in the localized release of any bound therapeutic substance at the site of insonation.
DUS-induced IC has been tested in pre-clinical studies to determine what effect it has on acute vascular and
microvascular thrombosis as well as nitric oxide (NO) release. These pre-clinical studies have consistently shown
that DUS-induced IC of LEP is effective in restoring coronary vascular and microvascular flow in acute ST segment
elevation myocardial infarction (STEMI), with microvascular flow improving even if upstream large vessel flow has
not been achieved. The initial clinical trials examining the efficacy of short pulse duration DUS high mechanical
index impulses in patients with STEMI are underway, and preliminary studies have suggested that earlier epicardial
vessel recanalization can be achieved prior to arriving in the cardiac catheterization laboratory. DUS high
mechanical index impulses have also been effective in pre-clinical studies for targeting DNA delivery that has
restored islet cell function in type I diabetes and restored vascular flow in the extremities downstream from a
peripheral vascular occlusion. Improvements in this technique will come from three dimensional arrays for
therapeutic applications, more automated delivery techniques that can be applied in the field, and use of
submicron-sized acoustically activated LEP droplets that may better permeate the clot prior to DUS activation
and cavitation. This article will focus on these newer developments for DUS therapeutic applications.
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Although diagnostic ultrasound (DUS) systems and
lipid-encapsulated perfluorocarbons (LEP) like Definity
(Lantheus Medical) or Sonazoid (GE Healthcare) have
been approved only for imaging applications; these two
products have significant therapeutic potential for non-
invasive targeted thrombolysis and drug delivery. Ultra-
sound and microbubbles alone as a method of dissolving* Correspondence: trporter@unmc.edu
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Tachibana and Tachibana demonstrating their potential
to augment the effects of lytic therapy [2]. Subsequent
in vivo studies demonstrated that ultrasound and micro-
bubbles alone, using low-frequency non-imaging trans-
ducers, could recanalize peripheral vascular thrombi
without fibrinolytic agents [3–5]. More recently, DUS
pressures, despite their short pulse duration, have
proven effective at recanalizing intravascular thrombotic
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capable of causing both stable cavitation and inertial
cavitation (IC). The intermittent application is necessary
for microbubble permeation into the thrombus, and IC
appears necessary, as this has been shown to create the
fluid jets that erode thrombus both from outside and
from within the thrombus infrastructure [6–8]. Subse-
quently, high mechanical index (MI) impulses from a
DUS system have been used in both pre-clinical and
clinical studies of acute ST segment elevation myocardial
infarction (STEMI) and ischemic stroke, achieving
successful coronary and cerebral recanalization with
improved microvascular flow without the need of
fibrinolytic therapy [9–14]. The DUS sequence has been
modified slightly in each of these applications, but it is
unclear how much of a modification beyond current
diagnostic limits are required to achieve effective throm-
bolysis and targeted drug delivery. Numerous small
animal studies have demonstrated the effectiveness of
DUS-guided high MI impulses in targeting DNA [13–16],
and more recent studies have demonstrated the potential
of DUS to target the delivery of inhibitory RNA to
suppress angiogenesis in adenocarcinoma [17, 18]. This
review will focus on the data that has been accumulated re-
garding DUS efficacy in thrombolysis and drug delivery in
large animals and how small modifications of current FDA-
approved LEP may further improve their clinical potential.Fig. 1 Very low MI images of a thrombosed arteriovenous graft when app
intravenous infusion of LEP. Small channels that slowly replenish early in th
channels that replenish more rapidly at 30–40 min of therapy. With permisReview
Targeted thrombolysis with DUS
The potential for intermittent high MI impulses from a
DUS transducer was first examined in a canine model of
arteriovenous graft thrombosis, where intermittent high
MI impulses (all <1.9 MI) were applied when low MI
imaging detected microbubbles within the risk area [6].
These high MI impulses were shown to induce IC within
the graft. The addition of the high MI impulses from a
DUS transducer (Acuson Sequoia 512 1.5 MHz) through
a 6-cm-thick tissue-mimicking phantom improved recana-
lization rates from 20 to 80 % after 30 min of treatment.
What was interesting in this model is that although angio-
graphically the vessel appeared to be occluded, low MI
contrast-sensitive imaging with the DUS transducer de-
tected microbubbles channeling through the thrombus be-
fore high MI impulses were applied (Fig. 1; Additional
file 1). This presence of microbubbles was also used to guide
when to apply high MI impulses; the small channels that
were angiographically invisible at the start of guided high
MI impulses progressed to larger channels with repeated
high MI impulses (Fig. 1). Furthermore, these channels
opened without any adjunctive fibrinolytic, anti-thrombotic,
or anti-platelet agents, suggesting that mechanical thrombus
dissolution was possible in the absence of pharmacotherapy.
Furthermore, no significant downstream embolization was
observed with ultrasound-induced recanalization.lying intermittent application of DUS high MI impulses during an
erapy (top row at 25–30 min of treatment) eventually become large
sion
Fig. 2 Parasternal short axis images and corresponding invasive angiograms of the left anterior descending during intermittent high MI applications
of DUS while using very low MI imaging to examine the risk area in between high MI applications. At 20–25 min into therapy, the replenishment of
myocardial contrast after a high MI application during the intravenous LEP microbubble infusion is more rapid and angiographic recanalization has
occurred (blue arrows)
Table 1 DUS-guided cavitation with commercial available
microbubbles: clinical applications in large animal models
Animal Microbubbles Transducer (MHz) Application
Porcine Lipid PFC 1.7 Catheter thrombi
Porcine Lipid PFC 1.7 Graft hygiene
Porcine Lipid PFC 1.7 Ischemic stroke
Human/porcine Definity 1.7 STEMI
PFC perfluorocarbon
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examined the efficacy of DUS high MI impulses in
restoring microvascular and epicardial blood flow in
porcine models of acute ST segment elevation myo-
cardial infarction, or STEMI [9–12]. These studies
demonstrated that these same DUS high MI impulses
were capable of restoring microvascular flow and function
(Fig. 2; Additional file 2) even if epicardial recanalization
was not achieved. Although epicardial recanalization rates
tripled with the addition of platelet-targeted microbubbles
and image-guided high MI DUS pulses, ST segment reso-
lution (indicating microvascular recanalization) was seen
with DUS high MI impulses even when epicardial recana-
lization was not observed, indicating that other potential
mediators were playing a role in restoring microvascular
flow. Subsequent studies in ischemic limb skeletal muscle
downstream from a peripheral vessel ligation have con-
firmed that high MI DUS of LEP microbubbles can induce
nitric oxide release, resulting in restoration of skeletal
microvascular flow, despite persistent upstream vessel
occlusion [15].
Slight prolongations in pulse duration on a DUS trans-
ducer may improve the amount of thrombus dissolution.
By increasing pulse duration from <5 to 20 μs on a DUS
transducer, a higher epicardial recanalization rate was
achieved with DUS-guided therapy added to ½ dose tis-
sue plasminogen activator. Despite the higher epicardial
recanalization rate, both short and longer pulse duration
high MI impulses were equally effective in ST segment
resolution and improvement in wall thickening within
the risk area [9]. The guided application of 20-μs pulse
duration high MI impulses during an intravenous LEP
microbubble infusion, without any fibrinolytic agent,was subsequently shown to produce equivalent epicar-
dial recanalization rates as full dose fibrinolytic therapy
in subsequent randomized comparisons in this same
porcine model of acute STEMI [10]. Although this slight
prolongation of pulse duration appears possible with
current DUS transducers, the safety of this longer pulse
duration has not been elucidated.
In an ischemic stroke, transcranial DUS and intraven-
ous LEP microbubbles, even in the absence of tissue
plasminogen activator, have recanalized intravascular
and microvascular thrombi in a large porcine animal
model [13]. In this model, the DUS was modified to pro-
vide an MI of 2.4 (pulse duration <5 μs, 1.7-MHz fre-
quency) for guided therapeutic impulses, while low MI
imaging was used to guide the applications. Other larger
animal models have been utilized to determine the po-
tential for transcranial ultrasound-induced cavitation of
microbubbles to reduce stroke size [16], but without
DUS pulse durations or imaging guidance. In humans,
the initial studies using a pulsed wave Doppler (PWD)
and systemically administered LEP in humans with acute
ischemic stroke have all combined microbubbles with
full dose fibrinolytic agents [17–19]. In the presence of
Table 2 Potential large animal application with DUS-targeted
gene delivery
Disease entity DUS frequency/
trigging
Specific gene Specific application




1:4 DNA-planned VGE Angiogenesis
Tumor DNA Tumor suppression
Tumor 1:10 ShRNA Anti-angiogenesis
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increasing the speed of intracranial recanalization, but
did also appear to increase the risk for intracranial
hemorrhage. No human trials of ischemic stroke have
examined the effect of targeted ultrasound-induced cavi-
tation alone, without fibrinolytic agents. Such trials are
needed and, based on acute STEMI studies, should be
done with guided intermittent application of the high
MI impulses. Table 1 lists the large animal studies thatFig. 3 Demonstration of reformation of beta cells (pink-stained cells) following D
D2/CDK4/GLP1 in high doses (panel d). Panel a demonstrates a normal baboon
b is UTMD control. Panel c is UTMD with low dose gene therapy. Bottom panelhave utilized DUS-targeted IC to clear thrombi in spe-
cific clinical settings.
Targeted drug and gene delivery with diagnostic
ultrasound
A considerable number of small animal studies have
demonstrated the ability of DUS-guided cavitation of
LEP to target the delivery of DNA or RNA ([20–22];
Table 2). The delivery of DNA or short hairpin (sh)
RNA can be achieved with binding of the nuclear mater-
ial to cationic microbubbles. The cationic charge is
achieved by altering the lipid composition of the micro-
bubble shell. Current FDA-approved microbubbles like
Definity (Lantheus Medical) do not have this charge and
thus would not be expected to bind the negatively
charged DNA or RNA [23]. There are few large animal
studies demonstrating the potential for DUS in this area,
but one group has now published preliminary studies for
DUS-guided plasmid delivery of DNA (cyclin D2/CDK4/
GLP1) in diabetic baboons to target the organizedUS-guided high MI-targeted delivery of plasmid DNA encoding for cyclin
pancreas. Note the numerous pink-stained cells that are now present. Panel
e demonstrates the fraction of beta cells present + US-guided therapies
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pancreas (Fig. 3; Additional file 3). If this can be consist-
ently demonstrated in a large non-human primate, the
potential for safe targeted gene delivery with DUS and
cationic LEP in humans should be evaluated [24, 25].
Conclusions
The use of a commercially available LEP and DUS for tar-
geted thrombolysis is now being tested in the first clinical
trials [14], with promising initial results. Targeted IC of
LEP has the potential not only to non-invasively and safely
dissolve intravascular and microvascular thrombi but
could also be effective in targeting gene delivery and has
been demonstrated to target the delivery of vascular endo-
thelial growth factors and genes for pancreatic regener-
ation. Diagnostic transducers have been modified in order
to provide radiofrequency feedback to confirm IC has oc-
curred, which may be necessary to confirm that a desired
microbubble response has occurred [26].
One problem with microbubbles is that they are con-
fined to intravascular spaces, and inertial cavitation can
only increase subendothelial delivery. The LEP can also
be formulated into droplets, even for the lower molecu-
lar weight fluorocarbons like octafluoropropane [27].
Since these droplets are nanometer scale, they can cross
endothelial membranes and reach interstitial spaces,
which may improve targeted delivery of genes into areas
of myocardial scar, and improve thrombolysis efficacy by
improving clot permeation prior to acoustic activation
and inertial cavitation. Studies are ongoing now to ex-
plore this new potential for DUS and LEP.
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